Loading stock data…
Grifols, S.A. (GRFS)
$7.75-0.05 (-0.64%)
Market ClosedLast close Sep 8
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grifols, S.A. in the Healthcare sector is trading at $7.75 with a market capitalization of $5.3B. Wall Street consensus targets $10.87 (2 analysts), implying a +40.2% move over the next 12 months. The stock is currently 24% below its 52-week high of $10.23, remaining 5.4% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +40.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.87B↑ | $1.70B↓ | $1.98B↑ | $1.89B↑ | $1.79B |
| Gross Profit | $705.00M↑ | $620.00M↓ | $686.84M↓ | $744.00M↑ | $695.00M |
| Operating Income | $329.00M↑ | $249.00M↓ | $275.38M↓ | $350.00M↑ | $274.00M |
| Net Income | $155.00M↑ | $73.00M↓ | $98.25M↓ | $117.00M↑ | $60.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.27B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.06
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.99%
Volume
Today's trading volume
298,388
Recent News
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher lat
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
European equities traded in the US as American depositary receipts were edging higher late Wednesday
Grifols (GRFS) Q2 2026 Earnings Call Transcript
CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.